NKB2 Stock Overview
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TG Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.96 |
| 52 Week High | US$32.71 |
| 52 Week Low | US$6.24 |
| Beta | 2.32 |
| 1 Month Change | -7.56% |
| 3 Month Change | -6.01% |
| 1 Year Change | -34.38% |
| 3 Year Change | -61.57% |
| 5 Year Change | 83.38% |
| Change since IPO | 302.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| NKB2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.4% | -4.3% | -2.5% |
| 1Y | -34.4% | -19.4% | -0.4% |
Return vs Industry: NKB2 underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: NKB2 underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| NKB2 volatility | |
|---|---|
| NKB2 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NKB2's share price has been volatile over the past 3 months.
Volatility Over Time: NKB2's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 264 | Mike Weiss | www.tgtherapeutics.com |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics, Inc. Fundamentals Summary
| NKB2 fundamental statistics | |
|---|---|
| Market cap | €1.88b |
| Earnings (TTM) | €11.91m |
| Revenue (TTM) | €219.53m |
159.8x
P/E Ratio8.7x
P/S RatioIs NKB2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKB2 income statement (TTM) | |
|---|---|
| Revenue | US$233.66m |
| Cost of Revenue | US$14.13m |
| Gross Profit | US$219.53m |
| Other Expenses | US$206.86m |
| Earnings | US$12.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.088 |
| Gross Margin | 93.95% |
| Net Profit Margin | 5.42% |
| Debt/Equity Ratio | 62.6% |
How did NKB2 perform over the long term?
See historical performance and comparison